OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Platzbecker on the FDA Approval of Luspatercept in Lower-Risk MDS

August 29th 2023

Uwe Platzbecker, MD, discusses the significance of the FDA approval of luspatercept for patients with lower-risk myelodysplastic syndrome with anemia.

Dr McKenzie on Updates to ASCO Treatment Guidelines in Metastatic Breast Cancer

August 28th 2023

Andrew McKenzie, PhD, discusses the updates to the ASCO clinical practice guidelines for biomarker testing in patients with metastatic breast cancer.

Dr Agarwal on the Benefit of PARP Inhibitors vs Chemotherapy in mCRPC

August 28th 2023

Neeraj Agarwal, MD, discusses the benefit of PARP inhibitors compared with chemotherapy in patients with metastatic castration-resistant prostate cancer.

Dr Barata on Staying Up to Date With Evolving Treatment Approaches in Kidney Cancer

August 28th 2023

Pedro Barata, MD, MSc, discusses the importance of staying up to date with evolving treatment approaches in kidney cancer.

Dr Islam on Novel Explorations of BTK Inhibitors in MCL and CLL

August 28th 2023

Prioty Islam, MD, MSc, discusses the exploration of novel roles for BTK inhibitors in the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Dr Halpern on the Investigation of Upfront Ruxolitinib and Navitoclax in Myelofibrosis

August 28th 2023

Anna B. Halpern, MD, discusses investigational efforts to utilize ruxolitinib and navitoclax in earlier treatment lines for patients with myelofibrosis.

Dr Williams on the Mechanism of Action of ADCs in Ovarian Cancer

August 25th 2023

Heather R. Williams, MD, discusses the mechanism of action of antibody-drug conjugates and ADC targets under investigation in patients with ovarian cancer.

Dr Mead on the Use of Zanubrutinib vs Ibrutinib in MCL

August 25th 2023

Monica D. Mead, MD, discusses the efficacy and safety differences between the second-generation BTK inhibitor zanubrutinib and the first-generation BTK inhibitor ibrutinib in patients with mantle cell lymphoma.

Dr Pothuri on the Phase 3 NRG-GY018 and RUBY Trials in Endometrial Cancer

August 25th 2023

Bhavana Pothuri, MD, discusses the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Dr Reichert on Key Research Questions in Prostate Cancer

August 25th 2023

Zachery Roger Reichert, MD, PhD, discusses key research questions to explore in early-stage prostate cancer.

Dr Barata on Immunotherapy Treatment and the Gut Microbiome in Kidney Cancer

August 25th 2023

Pedro Barata, MD, MSc, discusses important considerations regarding the relationship between immunotherapy treatment and the gut microbiome when treating patients with kidney cancer.

Dr Goetz on Post-CDK4/6 Inhibitor Treatment Options in HR-Positive Breast Cancer

August 25th 2023

Matthew P. Goetz, MD, discusses the available treatment options for patients with metastatic hormone receptor–positive breast cancer in the post-CDK inhibitor setting.

Dr Kremyanskaya on the Safety of Rusfertide in Phlebotomy-Dependent PV

August 25th 2023

Marina Kremyanskaya, MD, PhD, discusses the safety profile and future implications of rusfertide in the treatment of patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Dr Vaishampayan on the Use of Talazoparib and Enzalutamide in Patients With HRR Gene–Mutated mCRPC

August 24th 2023

Ulka Nitin Vaishampayan, MBBS, discusses the need for improved identification of patients with homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who may benefit from treatment with talazoparib and enzalutamide.

Dr Williams on Eye Toxicities Associated With ADCs in Ovarian Cancer

August 24th 2023

Heather R. Williams, MD, discusses ocular toxicities associated with antibody-drug conjugates and strategies for managing these toxicities in patients with ovarian cancer.

Dr. Ramaswamy on the Real-World Data Implications of Palbociclib in HR-Positive Breast Cancer

August 24th 2023

Bhuvaneswari Ramaswamy, MD, discusses the importance of real-world data when considering the efficacy of the CDK 4/6 inhibitor palbociclib in hormone receptor–positive breast cancer.

Dr Mead on the Decreased Use of Ibrutinib in Pretreated MCL

August 24th 2023

Monica D. Mead, MD, discusses reasons for the declining use of the BTK inhibitor ibrutinib in patients with mantle cell lymphoma.

Dr Kalemkerian on Unmet Needs With the Use of Chemoimmunotherapy in ES-SCLC

August 24th 2023

Gregory Peter Kalemkerian, MD, discusses the unmet needs associated with the investigation of combination chemoimmunotherapy in the frontline treatment of patients with extensive-stage small cell lung cancer.

Dr Kremyanskaya on the Promise of Rusfertide in Phlebotomy-Dependent PV

August 24th 2023

Marina Kremyanskaya, MD, PhD, discusses the potential advantages of using rusfertide to treat patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Dr Petrylak on Sequencing Questions in FGFR2/3-Altered Metastatic Urothelial Cancer

August 24th 2023

Daniel P. Petrylak, MD, discusses sequencing treatment selections in patients with FGFR2/3-altered metastatic urothelial cancer.